Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from aTyr Pharma

aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial

aTyr Pharma (NASDAQ:ATYR) said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C meeting. President and CEO Dr. Sanjay Shukla said the meeting, held in mid-April with official minu

Top 3 Health Care Stocks That May Explode In September

Top 3 Health Care Stocks That May Explode In September

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Martin Shkreli Is Shorting This ‘Strong Buy’ Penny Stock. How Should You Play Shares Here?

Martin Shkreli Is Shorting This ‘Strong Buy’ Penny Stock. How Should You Play Shares Here?

Martin Shkreli says aTyr stock could crash as much as 80% within the next six weeks. ATYR shares are not particularly attractive even without his warning.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary

Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares…

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug Application (NDA) for elacestrant for patients with ER+/HER2- advanced or metastatic breast cancer. The agency has granted Priority Review designation and assigned a target action date of February 17, 2023. Radius Health…

Earnings Outlook For aTyr Pharma

aTyr Pharma (NASDAQ:LIFE) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that aTyr Pharma will report an earnings per share (EPS) of $-0.33.

A Preview Of aTyr Pharma's Earnings

aTyr Pharma (NASDAQ:LIFE) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement. Analysts estimate that aTyr Pharma will report an earnings per share (EPS) of $-0.28.

inkl

Read news from The Economist, FT, and more,
with one subscription

3 Stocks Insiders Are Buying: Univar Solutions, aTyr Pharma And More

3 Stocks Insiders Are Buying: Univar Solutions, aTyr Pharma And More

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision.…

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Food and Drug Administration

Boston Scientific

US Food and Drug Administration

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Sickle Cell Disease

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play